Corynebacterium diphtheriae

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Corynebacterium diphtheriae
Accession Number
DB09877
Description

Corynebacterium diphtheriae toxin is extracted from the pathogenic actinobacterium C. diphtheriae that causes diphtheria. The bacteria culture is grown in a medium and through purification, diphtheria toxin is detoxified with formaldehyde and diafiltered. The vaccine is intramuscularly administered to provide active immunization against diphtheria in infants and children.

Type
Biotech
Groups
Approved, Investigational
Biologic Classification
Vaccines
Other vaccines
Synonyms
Not Available

Pharmacology

Indication
Not Available
Associated Conditions
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Products

Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
Prevnar 13Corynebacterium diphtheriae (34 mcg/0.5mL) + Streptococcus pneumoniae type 1 capsular polysaccharide antigen (2.2 mcg/0.5mL) + Streptococcus pneumoniae type 14 capsular polysaccharide antigen (2.2 mcg/0.5mL) + Streptococcus pneumoniae type 18c capsular polysaccharide antigen (2.2 mcg/0.5mL) + Streptococcus pneumoniae type 19a capsular polysaccharide antigen (2.2 mcg/0.5mL) + Streptococcus pneumoniae type 19f capsular polysaccharide antigen (2.2 mcg/0.5mL) + Streptococcus pneumoniae type 23f capsular polysaccharide antigen (2.2 mcg/0.5mL) + Streptococcus pneumoniae type 3 capsular polysaccharide antigen (2.2 mcg/0.5mL) + Streptococcus pneumoniae type 4 capsular polysaccharide antigen (2.2 mcg/0.5mL) + Streptococcus pneumoniae type 5 capsular polysaccharide antigen (2.2 mcg/0.5mL) + Streptococcus pneumoniae type 6a capsular polysaccharide diphtheria crm197 protein conjugate antigen (2.2 mcg/0.5mL) + Streptococcus pneumoniae type 6b capsular polysaccharide antigen (4.4 mcg/0.5mL) + Streptococcus pneumoniae type 7f capsular polysaccharide antigen (2.2 mcg/0.5mL) + Streptococcus pneumoniae type 9v capsular polysaccharide antigen (2.2 mcg/0.5mL)SuspensionIntramuscularPfizer Canada Ulc2010-03-01Not applicableCanada flag
Tetanus and Diphtheria Toxoids AdsorbedCorynebacterium diphtheriae (2.0 1/0.5mL) + Clostridium tetani (2.0 1/0.5mL)InjectionIntramuscularRebel Distributors1967-10-13Not applicableUS flag

Categories

Drug Categories
Not Available
Classification
Not classified

Chemical Identifiers

UNII
3U7E3O07S8
CAS number
Not Available

References

General References
Not Available
PubChem Substance
347910466
Wikipedia
Corynebacterium_diphtheriae

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4Active Not RecruitingPreventionChronic Kidney Disease (CKD)1
4CompletedDiagnosticImmune Response / Pneumonia / Streptococcus Pneumoniae1
4CompletedPreventionDiphtheria / Meningococcal / Pertussis Diseases / Streptococcal / Tetanus1
4CompletedPreventionDiphtheria / Pertussis / Tetanus1
4CompletedPreventionDiphtheria / Tetanus1
4CompletedTreatmentEnd Stage Renal Disease (ESRD)1
4RecruitingBasic ScienceHuman Immunodeficiency Virus (HIV) Infections / Human Immunodeficiency Virus Infection(HIV)/Acquired Immunodeficiency Syndrome (AIDS) / Human Immunodeficiency Virus Type 1 (HIV-1) Infection1
4RecruitingPreventionInfections, Pneumococcal / Infections, Streptococcus Pneumoniae / Invasive Pneumococcal Disease, Protection Against1
4RecruitingPreventionPlasma Cell Neoplasms1
4Unknown StatusPreventionPertussis1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
SuspensionIntramuscular
InjectionIntramuscular
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created on November 30, 2015 14:23 / Updated on June 12, 2020 10:52

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates